Literature DB >> 15916492

A model to provide comprehensive testing for HIV, viral hepatitis, and sexually transmitted infections at a short-term drug treatment center.

Michelle A Lally1, Ryan MacNevin, Ziad Sergie, Robert Hitt, Melissa DiSpigno, Carly Cenedella, Michael D Stein.   

Abstract

Substance users are at high risk for blood-borne infections as well as those that are transmitted sexually. Substance abuse treatment centers present an opportunity to offer comprehensive counseling and testing (CCT) for HIV, viral hepatitis, and sexually transmitted infections (STIs) to this high-risk population. We examined the feasibility and acceptability of one model of CCT among substance users. CCT was offered to 145 consecutive inpatients; study participants completed a risk factor questionnaire and selected from a menu of testing options. Thirty-six percent of those approached agreed to participate and accepted at least one biologic test. Sixty-two percent of participants accepted all tests that were offered. While beneficial to those who accept testing, the described model of CCT is feasible in a drug treatment center, but acceptable to only a minority of inpatients.

Entities:  

Mesh:

Year:  2005        PMID: 15916492      PMCID: PMC1852463          DOI: 10.1089/apc.2005.19.298

Source DB:  PubMed          Journal:  AIDS Patient Care STDS        ISSN: 1087-2914            Impact factor:   5.078


  16 in total

1.  Access to medical care and service utilization among injection drug users with HIV/AIDS.

Authors:  A R Knowlton; D R Hoover; S E Chung; D D Celentano; D Vlahov; C A Latkin
Journal:  Drug Alcohol Depend       Date:  2001-09-01       Impact factor: 4.492

2.  Satisfaction with access to health care among injection drug users, other drug users, and nonusers.

Authors:  Dale D Chitwood; Mary Comerford; H Virginia McCoy
Journal:  J Behav Health Serv Res       Date:  2002-05       Impact factor: 1.505

3.  The importance of routine HIV testing in the incarcerated population: the Rhode Island experience.

Authors:  Amar A Desai; E Timothy Latta; Anne Spaulding; Josiah D Rich; Timothy P Flanigan
Journal:  AIDS Educ Prev       Date:  2002-10

4.  Risk and prevalence of treatable sexually transmitted diseases at a Birmingham substance abuse treatment facility.

Authors:  L H Bachmann; I Lewis; R Allen; J R Schwebke; L C Leviton; H A Siegal; E W Hook
Journal:  Am J Public Health       Date:  2000-10       Impact factor: 9.308

5.  Acceptability of sexually transmitted infection screening among women in short-term substance abuse treatment.

Authors:  Michelle A Lally; Sara Alvarez; Ryan Macnevin; Carly Cenedella; Melissa Dispigno; Joseph I Harwell; David Pugatch; Timothy P Flanigan
Journal:  Sex Transm Dis       Date:  2002-12       Impact factor: 2.830

Review 6.  Hepatitis C virus infection: an overview.

Authors:  S J Hwang
Journal:  J Microbiol Immunol Infect       Date:  2001-12       Impact factor: 4.399

7.  Linkage to medical services in the Drug Abuse Treatment Outcome Study.

Authors:  P D Friedmann; S C Lemon; M D Stein; R M Etheridge; T A D'Aunno
Journal:  Med Care       Date:  2001-03       Impact factor: 2.983

8.  Sexual risk behaviours and STIs in drug abuse treatment populations whose drug of choice is crack cocaine.

Authors:  Michael W Ross; Lu-Yu Hwang; Carolyn Zack; Lara Bull; Mark L Williams
Journal:  Int J STD AIDS       Date:  2002-11       Impact factor: 1.359

Review 9.  Hepatitis C virus infection: 10 years after the discovery of the virus.

Authors:  G Ramadori; V Meier
Journal:  Eur J Gastroenterol Hepatol       Date:  2001-05       Impact factor: 2.566

10.  HIV testing in the setting of inpatient acute substance abuse treatment.

Authors:  D Pugatch; B Levesque; S Greene; L Strong; T Flanigan; M Lally
Journal:  Am J Drug Alcohol Abuse       Date:  2001-08       Impact factor: 3.829

View more
  8 in total

1.  HIV testing in correctional agencies and community treatment programs: the impact of internal organizational structure.

Authors:  Carrie B Oser; Michele Staton Tindall; Carl G Leukefeld
Journal:  J Subst Abuse Treat       Date:  2007-03-09

2.  HIV screening practices in U.S. hospitals, 2009-2010.

Authors:  Andrew C Voetsch; James D Heffelfinger; Juliet Yonek; Pragna Patel; Steven F Ethridge; Gretchen W Torres; Margaret A Lampe; Bernard M Branson
Journal:  Public Health Rep       Date:  2012 Sep-Oct       Impact factor: 2.792

3.  Characteristics of substance abuse treatment programs providing services for HIV/AIDS, hepatitis C virus infection, and sexually transmitted infections: the National Drug Abuse Treatment Clinical Trials Network.

Authors:  Lawrence S Brown; Steven Allan Kritz; R Jeffrey Goldsmith; Edmund J Bini; John Rotrosen; Sherryl Baker; Jim Robinson; Patrick McAuliffe
Journal:  J Subst Abuse Treat       Date:  2006-06

4.  Gender and age disparities in the prevalence of Chlamydia infection among sexually active adults in the United States.

Authors:  Hind A Beydoun; Jessica Dail; Hala Tamim; Bethrand Ugwu; May A Beydoun
Journal:  J Womens Health (Larchmt)       Date:  2010-10-15       Impact factor: 2.681

5.  A qualitative study among injection drug using women in Rhode Island: attitudes toward testing, treatment, and vaccination for hepatitis and HIV.

Authors:  Michelle A Lally; Sydney A Montstream-Quas; Sara Tanaka; Sara K Tedeschi; Kathleen M Morrow
Journal:  AIDS Patient Care STDS       Date:  2008-01       Impact factor: 5.078

6.  Integration and co-location of HIV/AIDS, tuberculosis and drug treatment services.

Authors:  Laurie Sylla; R Douglas Bruce; Adeeba Kamarulzaman; Frederick L Altice
Journal:  Int J Drug Policy       Date:  2007-05-10

7.  Patients at a drug detoxification center share perspectives on how to increase hepatitis C treatment uptake: A qualitative study.

Authors:  Sabrina A Assoumou; Carlos R Sian; Christina M Gebel; Benjamin P Linas; Jeffrey H Samet; Judith A Bernstein
Journal:  Drug Alcohol Depend       Date:  2021-01-11       Impact factor: 4.492

8.  Reducing substance use and risky sexual behaviour among drug users in Durban, South Africa: Assessing the impact of community-level risk-reduction interventions.

Authors:  C D H Parry; T Carney; P Petersen Williams
Journal:  SAHARA J       Date:  2017-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.